Gossamer Bio Inc
Închisă
SectorSănătate
0.16
Rezumat
Modificarea prețului
24h
Minim
0.16
Maxim
0.16
Venit | 574K -47M |
|---|---|
Vânzări | 3.2M 17M |
EPS | -0.2 |
Marjă de profit | -275.223 |
Angajați | 161 |
EBITDA | 1.2M -45M |
Recomandări | Neutru |
|---|---|
Prognoză pe 12 luni | +3225% upside |
Următoarele câștiguri | 3 aug. 2026 |
|---|
Capitalizare de piață | -38M 41M |
|---|---|
Deschiderea anterioară | 0.16 |
Închiderea anterioară | 0.16 |
Sentimentul știrilor
By Acuity
47%
53%
133 / 342 Clasament în Healthcare
Gossamer Bio Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.